Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

AMRI reports $47.7 million total revenue for the third quarter of 2009

AMRI today reported financial and operating results for the third quarter ended September 30, 2009.

9 Nov 2009

Caliper Discovery Alliances and Services receives a $1.8M funding commitment for the EPA's ToxCast program

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $1.8 million under its contract with the Environmental Protection Agency (EPA) for the EPA's ToxCast screening program.

9 Nov 2009

Locus Pharmaceuticals creates a new division, Ansaris

Locus Pharmaceuticals, a drug company that has developed its own internal and partnered pipeline, focusing on oncology, immunology, and inflammatory targets, today announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

7 Nov 2009

Quintiles opens expanded regional headquarters facility in Singapore

To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced the official grand opening of its expanded regional headquarters facility in Singapore’s Science Park I.

6 Nov 2009

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.

6 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

SCYNEXIS receives payment as part of pharmaceutical discovery program with Merial

Merial Limited and SCYNEXIS, Inc. announced today that SCYNEXIS has earned a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005.

5 Nov 2009

Micro-injector may help rapid development of new generation of drugs

It's no bigger than a stamp packet but it has the potential to allow rapid development of a new generation of drugs and genetic engineering organisms, and to better control in-vitro fertilization.

5 Nov 2009

Emerson Resources announces partnership with Bio Research

Emerson Resources, Inc., a premier pharmaceutical solutions company, today announced that it has formed a strategic partnership with Bio Research, a contract research organization that specializes in the agrichemical and related industries, to further extend its business development capabilities. The exclusive partnership leverages the expertise of industry veteran Robert Westbrook, CEO of Bio Research, who is spearheading Emerson Resources' intensified business development and sales efforts.

4 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

Scientists identify compounds that hold promise for treating parasitic infection

Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases.

4 Nov 2009

Financial results for third-quarter 2009 announced by Combinatorx

CombinatoRx, Incorporated today reported financial results for the third quarter ended September 30, 2009.

3 Nov 2009

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

SRU Biosystems today announced that Caliper Life Sciences will use SRU Biosystems’ label-free BIND® technology to offer new functional assays as part of its Discovery Alliances and Services.

3 Nov 2009

MDS sells its Central Labs operations to Czura Thornton

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has completed the divestiture of its Central Labs operations to Czura Thornton, a private investment group based in Jersey, Channel Islands.

From Danaher 2 Nov 2009

London Genetics enters an intensive partnering programme

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September.

31 Oct 2009

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009.

29 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

PPD, Inc. today announced its board of directors has authorized management to proceed with preparations to spin off its compound partnering business from its core contract research organization, or CRO, business.

28 Oct 2009

Drug Discovery News and Research

Further Reading

AMRI reports $47.7 million total revenue for the third quarter of 2009

Caliper Discovery Alliances and Services receives a $1.8M funding commitment for the EPA's ToxCast program

Locus Pharmaceuticals creates a new division, Ansaris

Quintiles opens expanded regional headquarters facility in Singapore

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

SCYNEXIS receives payment as part of pharmaceutical discovery program with Merial

Micro-injector may help rapid development of new generation of drugs

Emerson Resources announces partnership with Bio Research

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Scientists identify compounds that hold promise for treating parasitic infection

Financial results for third-quarter 2009 announced by Combinatorx

Caliper Life Sciences to use SRU Biosystems’ label-free BIND technology for new functional assays

MDS sells its Central Labs operations to Czura Thornton

London Genetics enters an intensive partnering programme

Supportive data from a preclinical study of SCY-635 to be presented

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

PPD plans to separate compound partnering business from CRO business; spin-off to result in independent public companies

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News